Skip to content

Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration

Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00793767
Enrollment
10
Registered
2008-11-19
Start date
2009-01-31
Completion date
Unknown
Last updated
2009-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Sensitivity

Keywords

Erythropoietin, human muscle tissue, insulin sensitivity, substrate metabolism

Brief summary

Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.

Detailed description

Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.

Interventions

DRUGerythropoietin

bolus of 400 IU/kg

DRUGplacebo (saline)

i.v

Sponsors

Aarhus University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy persons * Between 18 and 30 years * Normal weight (BMI: 18-25)

Exclusion criteria

* Severe heart disease (NYHA 3) * Uncontrolled hypertension * Previous cerebrovascular disease * Proliferative retinopathy * Diabetes * Musculo-skeletal diseases

Design outcomes

Primary

MeasureTime frame
Insulin sensitivity4 and 6 hours post

Secondary

MeasureTime frame
Substrate metabolism4 and 6 hours post

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026